Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHASTA-10 long-term extension study of plozasiran in adults with hypertriglyceridemia
2024-519712-13-00Phase 3Authorised
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of plozasiran in hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Dec 2025; status: authorised.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2024-519712-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519712-13-00.